

6. (Amended) A method according to claim 1 wherein prior to step (1) the cells in the starting sample are depleted of CD14<sup>+</sup>, CD16<sup>+</sup>, CD19<sup>+</sup>, CD56<sup>+</sup> and glycophorin A<sup>+</sup> cells.

7. (Amended) A method according to claim 1 wherein prior to step (1) the cells in the starting sample are depleted of TcR $\alpha\beta$ <sup>+</sup> T cells.

8. (Amended) A method according claim 1 wherein prior to step (1) the cells in the starting sample are depleted of non-TcR $\gamma\delta$ <sup>+</sup> T cells.

9. (Amended) A method according to claim 1 wherein the starting sample is selected from peripheral blood, bone marrow, lymphoid tissue, epithelia, thymus, liver, spleen, cancerous tissue, infected tissue, lymph node tissue or fractions thereof.

11. (Amended) A method according to claim 1 wherein the starting sample is low density mononuclear cells.

12. (Amended) A method according to claim 1 wherein in the first culture medium the T cell mitogen is present in an amount from about 0.01 to about 100  $\mu\text{g/ml}$ ; the IL-2 is present in an amount from about 0.1 to about 1000 ng/ml and the IL-4 is present in an amount from about 0.1 to about 1000 ng/ml.

13. (Amended) A method according to claim 1 wherein in the first culture medium the T cell mitogen is present in an amount from about 0.1 to about 50  $\mu\text{g/ml}$ ; the IL-2 is present in an amount from about 1 to about 100 ng/ml and the IL-4 is present in an amount from about 1 to about 100 ng/ml.

14. (Amended) A method according to claim 1 wherein in the first culture medium the T cell mitogen is present in an amount from about 0.5 to about 10  $\mu\text{g/ml}$ ; the IL-2 is present in an amount from about 2 to about 50 ng/ml and the IL-4 is present in an amount from about 2 to about 50 ng/ml.

15. (Amended) A method according to claim 1 wherein the first culture medium comprises 1 $\mu$ g/mL of a T cell mitogen; 10 ng/mL IL-2 and 10 ng/mL IL-4.

16. (Amended) A method according to claim 1 wherein the T cell mitogen is concanavalin A.

21. (Amended) A method according to claim 1 wherein in the second culture medium the IL-2 is present in an amount from about 0.1 to about 1000 ng/ml and the IL-4 is present in an amount from about 0.1 to about 1000 ng/ml.

22. (Amended) A method according to claim 1 wherein in the second culture medium the IL-2 is present in an amount from about 1 to about 100 ng/ml and the IL-4 is present in an amount from about 1 to about 100 ng/ml.

23. (Amended) A method according claim 1 wherein in the second culture medium the IL-2 is present in an amount from about 2 to about 50 ng/ml and the IL-4 is present in an amount from about 2 to about 50 ng/ml.

24. (Amended) A method according claim 1 wherein the second culture medium comprises 10 ng/mL IL-2 and 10 ng/mL IL-4.

32. (Amended) A cell preparation enriched in TcR $\gamma\delta$ <sup>+</sup> T cells prepared according to the method of claim 1.

34. (Amended) A cell preparation according to claim 32 wherein greater than 80% of the total cells are TcR $\gamma\delta$ <sup>+</sup> T cells.

35. (Amended) A cell preparation according to claim 32 wherein greater than 90% of the total cells are TcR $\gamma\delta$ <sup>+</sup> T cells.

36. (Amended) A cell preparation according to claim 32 which comprises V $\delta$ 1<sup>+</sup> and V $\delta$ 2<sup>+</sup> TcR $\gamma\delta$ <sup>+</sup> T cells.

39. (Amended) A use of a cell preparation according to claim 32 to prepare a medicament to modulate an immune response.

40. (Amended) A use of a cell preparation according to claim 32 to prepare a medicament to treat an infection.

41. (Amended) A use of a cell preparation according to claim 32 to prepare a medicament to treat cancer.

42. (Amended) A use of a cell preparation according to claim 32 to prepare a medicament to treat chronic myelogenous leukemia.

43. (Amended) A use of a cell preparation according to claim 32 to prepare a vaccine.

44. (Amended) A method of modulating an immune response comprising administering an effective amount of  $TcR\gamma\delta^+$  T cells obtained according to the method of claim 1 to an animal in need thereof.

45. (Amended) A method for treating an infection comprising administering an effective amount of  $TcR\gamma\delta^+$  T cells obtained according to the method of claim 1 to an animal in need thereof.

46. (Amended) A method for treating cancer comprising administering an effective amount of  $TcR\gamma\delta^+$  T cells obtained according to the method of claim 1 to an animal in need thereof.

47. (Amended) A method for treating chronic myelogenous leukemia comprising administering an effective amount of  $TcR\gamma\delta^+$  T cells obtained according to the method of claim 1 to an animal in need thereof.